Takeda Pharmaceutical Files Routine 6-K Disclosure

TL;DR

Takeda filed a 6-K, just routine paperwork for April. Nothing new to see here.

AI Summary

Takeda Pharmaceutical Company Limited filed a Form 6-K on April 15, 2024, to report information as a foreign private issuer. The filing does not contain specific financial figures or operational updates but serves as a routine disclosure for the month of April 2024. Takeda is registered with the SEC under file number 001-38757 and is headquartered in Tokyo, Japan.

Why It Matters

This filing indicates Takeda is fulfilling its ongoing reporting obligations as a foreign private issuer with the U.S. Securities and Exchange Commission.

Risk Assessment

Risk Level: low — This is a routine administrative filing with no new material financial or operational information disclosed.

Key Players & Entities

• TAKEDA PHARMACEUTICAL COMPANY LIMITED (company) — Filer
• 0001395064-24-000027 (filing_id) — Accession Number
• 001-38757 (company_id) — SEC File Number
• 20240415 (date) — Filing Date

FAQ

Filing Documents

• form6k_041524.htm (6-K) — 33KB
• 0001395064-24-000027.txt ( ) — 34KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date April 15, 2024 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller News Release Notice Regarding Issuance of JPY Hybrid Bonds OSAKA, Japan, April 15, 2024 – Takeda Pharmaceutical Company Limited (Head Office Chuo-ku, Osaka (TSE4502NYSETAK), " Takeda ") today announced that it will issue its 2 nd Unsecured, Interest Deferrable and Early Redeemable Subordinated Bonds ("the 2 nd Hybrid Bonds") in the form of a public offering in Japan to refinance the whole or part of the 1 st Unsecured, Interest Deferrable and Early Redeemable Subordinated Bonds ("the 1 st Hybrid Bonds") that were issued on June 6, 2019. In preparation for the upcoming issue in 2024, Takeda today filed an Amended Shelf Registration Statement for the issuance of the 2 nd Hybrid Bonds with the Director of the Kanto Local Finance Bureau. 1. Purpose and Background of the 2 nd Hybrid Bonds Issuance Takeda issued the 1 st Hybrid Bonds of JPY 500 billion in June 2019 after the acquisition of Shire plc. As a result, hybrid bonds have formed an important part of Takeda's capital structure, and this importance remains unchanged. With the 1 st Hybrid Bonds approaching their First Call Date on October 6, 2024, Takeda plans to replace the 1 st Hybrid Bonds with the proceeds from the issuance of the 2 nd Hybrid Bonds and (if needed) Hybrid Loans having similar terms. 2. Features of the 2 nd Hybrid Bonds The 2 nd Hybrid Bonds will contain features of debt and equity. As a debt instrument they will carry an interest coupon and have a final maturity date. As an equity instrument they will be subordinated to Senior Notes and other debt instruments, allow interest coupon deferral, and have a very long maturity of up to 60 Years. Given

Forward-Looking Statements

Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could", "anticipates", "estimates", "projects" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States competitive pressures and developments changes to applicable laws and regulations, including global health care reforms challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof uncertainty of commercial success for new and existing products manufacturing difficulties or delays fluctuations in interest and currency exchange rates claims or concerns regarding the safety or efficacy of marketed products or product candidates the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business the timing and impact of post-merger integration efforts with acquired companies the ability to divest assets that are not core to Takeda's operations and the timing of any such divestment(s) and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda

View Full Filing

View this 6-K filing on SEC EDGAR